Our CD16A/GPC3 BsAb platform addresses two unmet needs in HCC immunotherapy: (1) the lack of clinically advanced NK cell-engaging BsAbs and (2) the suboptimal synergy between existing BsAbs and TKIs. This evidence concerns the gene FCGR3A and hepatocellular carcinoma.